15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $65.2B | $20.6B | 83.0% | 0.0% | — | $42.5B | $7.3B |
| 2024 | $45.0B | $10.6B | 81.3% | 0.0% | — | $33.6B | $3.3B |
| 2023 | $34.1B | $5.2B | 79.2% | 0.0% | — | $25.2B | $2.8B |
| 2022 | $28.5B | $6.2B | 76.8% | 0.0% | — | $16.2B | $2.1B |
| 2021 | $28.3B | $5.6B | 74.2% | 0.0% | — | $16.9B | $3.8B |
| 2020 | $24.5B | $6.2B | 77.7% | 0.0% | — | $16.6B | $3.7B |
| 2019 | $22.3B | $8.3B | 78.8% | 0.0% | — | $15.3B | $2.3B |
| 2018 | $21.5B | $3.2B | 78.2% | 0.0% | — | $10.3B | $7.3B |
| 2017 | $20.0B | -$204M | 77.7% | 0.0% | — | $13.6B | $6.2B |
| 2016 | $18.3B | $2.7B | 77.3% | 0.0% | — | $10.3B | $4.6B |
| 2015 | $20.0B | $2.4B | 0.0% | 0.0% | — | $8.0B | $3.7B |
| 2014 | $19.6B | $2.4B | 0.0% | 0.0% | — | $8.0B | $3.9B |
| 2013 | $23.1B | $4.7B | 0.0% | 0.0% | — | $5.2B | $3.8B |
| 2012 | $22.6B | $4.1B | 0.0% | 0.0% | — | $5.5B | $4.0B |
| 2011 | $24.3B | $4.3B | 0.0% | 0.0% | — | $7.0B | $5.9B |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $19.8B | $7.4B | 81.9% | 0.0% | — | $39.4B | $5.3B |
| Dec '25 | $19.3B | $6.6B | 82.5% | 0.0% | — | $42.5B | $7.3B |
| Sep '25 | $17.6B | $5.6B | 82.9% | 0.0% | — | $40.9B | $9.8B |
| Jun '25 | $15.6B | $5.7B | 84.3% | 0.0% | — | $34.2B | $3.4B |
| Mar '25 | $12.7B | $2.8B | 82.5% | 0.0% | — | $34.5B | $3.1B |
| Dec '24 | $13.5B | $4.4B | 82.2% | 0.0% | — | $33.6B | $3.3B |
| Sep '24 | $11.4B | $970M | 81.0% | 0.0% | — | $29.0B | $3.4B |
| Jun '24 | $11.3B | $3.0B | 80.8% | 0.0% | — | $23.7B | $3.2B |
| Mar '24 | $8.8B | $2.2B | 80.9% | 0.0% | — | $24.6B | $2.5B |
| Dec '23 | $9.4B | $2.2B | 80.9% | 0.0% | — | $25.2B | $2.8B |
| Sep '23 | $9.5B | -$57M | 80.4% | 0.0% | — | $17.9B | $2.4B |
| Jun '23 | $8.3B | $1.8B | 78.3% | 0.0% | — | $18.2B | $2.7B |
| Mar '23 | $7.0B | $1.3B | 76.6% | 0.0% | — | $18.9B | $3.5B |
| Dec '22 | $7.3B | $1.9B | 78.8% | 0.0% | — | $16.2B | $2.1B |
| Sep '22 | $6.9B | $1.5B | 77.3% | 0.0% | $1.6B | $14.1B | $2.6B |
| Jun '22 | $6.5B | $953M | 78.0% | 0.0% | $812M | $14.7B | $2.6B |
| Mar '22 | $7.8B | $1.9B | 73.5% | 0.0% | $2.2B | $15.2B | $2.5B |
| Dec '21 | $8.0B | $1.7B | 74.4% | 0.0% | — | $16.9B | $3.8B |
| Sep '21 | $6.8B | $1.1B | 78.9% | 0.0% | $1.3B | $15.5B | $3.8B |
| Jun '21 | $6.7B | $1.4B | 71.0% | 0.0% | $1.4B | $14.7B | $3.2B |
How the market has priced LLY against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Lilly (Eli)'s revenue has grown 21.6% per year, and net income grown 27.2% per year. These are computed facts, not advice.
As of FY2025, Lilly (Eli) reported $42.5B of total debt against $7.3B of cash.
In FY2025, gross margin was 83.0%, operating margin —, and net margin 31.7%.
As of Jun '26, Lilly (Eli) traded at a price-to-earnings ratio of about 51.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.